Loading...
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study
Caimi, P. F. Ai, W. Z. Alderuccio, J. P. Ardeshna, K. M. Hamadani, M. Hess, B. Kahl, B. S. Radford, John Solh, M. Stathis, A.
Caimi, P. F.
Ai, W. Z.
Alderuccio, J. P.
Ardeshna, K. M.
Hamadani, M.
Hess, B.
Kahl, B. S.
Radford, John
Solh, M.
Stathis, A.
Citations
Altmetric:
Abstract
Therapies that demonstrate durable, long-term responses with manageable safety and tolerability are needed for patients with relapsed/refractory diffuse large B -cell lymphoma (R/R DLBCL). Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]), an anti-CD19 antibody conjugated to a potent pyrrolobenzodiazepine dimer, demonstrated single -agent antitumor activity in the pivotal phase II LOTIS-2 study in heavily pretreated patients with R/R DLBCL. Here we present updated efficacy and safety analyses from LOTIS-2, performed for all patients and in subsets of patients with a complete response (CR), including patients with CR who were event -free (no progressive disease or death) for >= 1 year and >= 2 years from cycle 1, day 1 of treatment. Lonca was administered every 3 weeks (0.15 mg/kg for 2 cycles; 0.075 mg/kg for subsequent cycles). As of the final data cutoff (September 15, 2022; median follow-up: 7.8 months [range, 0.3-42.6]), 70 of 145 (48.3%) patients achieved an overall response. Thirty-six (24.8%) patients achieved CR, of which 16 (44%) and 11 (31%) were event -free for >= 1 year and >= 2 years, respectively. In the all -treated population, the median overall survival was 9.5 months; the median progression -free survival was 4.9 months. Among patients with CR, median overall survival and progression -free survival were not reached, with 24 -month overall and progression -free survival rates of 68.2% (95% CI: 50.0-81.0) and 72.5% (95% CI: 48.2-86.8), respectively. No new safety concerns were detected. With additional follow-up, Lonca continued to demonstrate durable, long-term responses with manageable safety and tolerability in patients with CR (clinicaltrials gov. Identifier: NCT03589469).
Description
Date
2024
Publisher
Collections
Files
Keywords
Type
Article
Citation
Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica. 2024 APR;109(4):1184-93. PubMed PMID: WOS:001197029900001. English.